This task force report provides evidence-based recommendations for the modalities and frequency of cardiovascular monitoring in long-term survivors of childhood cancer.
Answers are grounded in this paper and cite their sources.
Informs cardiovascular surveillance in childhood cancer survivors; extends literature synthesis into evidence-based monitoring recommendations.
Curative therapy for childhood cancer has improved significantly in the last 2 decades such that, at present, approximately 80% of all children with cancer are likely to survive > or = 5 years after diagnosis. Prevention, early diagnosis, and treatment of long-term sequelae of therapy have become increasingly more significant as survival rates continue to improve. Cardiovascular disease is a well-recognized cause of increased late morbidity and mortality among survivors of childhood cancer. The Children's Oncology Group Late Effects Committee and Nursing Discipline and Patient Advocacy Committee have recently developed guidelines for follow-up of long-term survivors of pediatric cancer. A multidisciplinary task force critically reviewed the existing literature to evaluate the evidence for the cardiovascular screening recommended by the Children's Oncology Group guidelines. In this review we outline the clinical manifestations of late cardiovascular toxicities, suggest modalities and frequency of monitoring, and address some of the controversial and unresolved issues regarding cardiovascular disease in childhood cancer survivors.
No takes yet. Share an insight, caveat, or question.
Shankar et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: